Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...
Moderna’s recent stock drop reflects investor concerns over the company’s revised financial outlook and strategic shifts. Despite its pioneering role in mRNA technology and promising future prospects, ...